Abstract
Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.
| Original language | English |
|---|---|
| Title of host publication | The Future of Drug Discovery |
| Subtitle of host publication | Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery |
| Publisher | Elsevier Inc. |
| Pages | 1-4369 |
| Number of pages | 4369 |
| Volume | 1-8 |
| ISBN (Electronic) | 9780128032008 |
| ISBN (Print) | 9780128032015 |
| State | Published - 3 Jun 2017 |
Fingerprint
Cite this
}
Comprehensive Medicinal Chemistry III. / Chackalamannil, Samuel; Rotella, David; Ward, Simon E.
The Future of Drug Discovery: Drug Discovery Technologies: In Silico Drug Discovery Tools: Experimental Adme and Toxicology: Cancer, Immunology and Inflammation, and Infectious Disease: Biologics Medicine: Cns, Pain, Metabolic Syndrome, Cardiovascular, Tissue Fibrosis and Urinary Incontinence: Case Histories in Recent Drug Discovery. Vol. 1-8 Elsevier Inc., 2017. p. 1-4369.Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Comprehensive Medicinal Chemistry III
AU - Chackalamannil, Samuel
AU - Rotella, David
AU - Ward, Simon E.
PY - 2017/6/3
Y1 - 2017/6/3
N2 - Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.
AB - Biopharmaceuticals are now becoming an innovative strategy for developing new therapeutic agents. The field of biologics medicine is expanding into new areas of molecular diversity, which comprises polypeptides, oligonucleotides (DNA, siRNA, microRNA), antibodies (monoclonal and conjugated antibodies), and PNA (peptide nucleic acid) structures. The aim of introducing biologics medicine to the Comprehensive Medicinal Chemistry series is to present an overview of different large molecule drug modalities and the innovative science and challenges involved in developing biologics-based medicine. Biopharmaceuticals are in an earlier stage of development relative to small molecules, but the field is progressing exponentially. Advances in the basic science and application of technologies related to DNA/RNA heteroduplex oligonucleotide, antisense oligonucleotide (ASO) mRNA/protein, and transformative heterodimeric IgG bispecific antibodies including clinical evaluation of drug candidates in the field are accelerating.
UR - http://www.scopus.com/inward/record.url?scp=85041583558&partnerID=8YFLogxK
M3 - Chapter
AN - SCOPUS:85041583558
SN - 9780128032015
VL - 1-8
SP - 1
EP - 4369
BT - The Future of Drug Discovery
PB - Elsevier Inc.
ER -